Read more
from combining radiation with a molecular targeted agent - namely cetuximab, a recombinant mouse/human chimeric monoclonal antibody against the Epidermal Growth Factor (EGF) receptor [4] Astsaturov, Cohen and Harari present a more indepth review of the biology of the EGF Receptor and its signaling pathway in Chap. 7 as a potential target in combination with fractionated radiotherap y for head and neck squamous cell carcinoma (HNSCC). A flurry of agents are under de velopment for targeting EGFR and in March 2006, the US Food and Drugs Administration approved cetuximab combined with radiation as a primary treatment option for patients with loco-regionally advanced HNSCC in whom chemoradiation therapy is deemed not to be an option. While blocking the EGF pathway during fractionated radiotherapy may seem an obvious strategy [5], the rationale for combining antiangiogenic and antivascular targeting agents with radiation may be less intuitive. However, recent research shows that there are several reasons why this could result in a therapeutic gain in practice. Chapter 8 is a review of this rapidly expanding field by Citrin and Camphausen. Targeted agents combined with radiation may offer new opportunities in the treatment of central nervous system malignancies, a tumor type where the outlook remains poor despite some recent progress [6]. Current attempts to overcome rad- tion resistance in these tumors on the basis of an improved understanding of their molecular biology are the topic of Chap. 9 by Chakravarti and Palanichamy.
List of contents
Advances in Imaging and Biologically-Based Treatment Planning.- Radiation Oncology Advances: An Introduction.- Advanced Image-Guided External Beam Radiotherapy.- Dose Painting and Theragnostic Imaging: Towards the Prescription, Planning and Delivery of Biologically Targeted Dose Distributions in External Beam Radiation Oncology.- Molecular and Functional Imaging in Radiation Oncology.- Prognostic and Predictive Markers in Radiation Therapy: Focus on Prostate Cancer.- Advances in Molecular Biology and Targeted Therapies.- Overview of Cancer Molecular Radiobiology.- Clinical Application of EGFR Inhibitors in Head and Neck Squamous Cell Cancer.- Advancement of Antiangiogenic and Vascular Disrupting Agents Combined with Radiation.- Overcoming Therapeutic Resistance in Malignant Gliomas: Current Practices and Future Directions.- Advances in Treatment Delivery and Planning.- Advances in Intensity-Modulated Radiotherapy Delivery.- Image-Based Modeling of Normal Tissue Complication Probability for Radiation Therapy.- Optimization of Radiotherapy Using Biological Parameters.- Clinical Advances.- Combined Chemoradiotherapy Advances.- Cytoprotection for Radiation-Associated Normal Tissue Injury.
Summary
from combining radiation with a molecular targeted agent – namely cetuximab, a recombinant mouse/human chimeric monoclonal antibody against the Epidermal Growth Factor (EGF) receptor [4] Astsaturov, Cohen and Harari present a more indepth review of the biology of the EGF Receptor and its signaling pathway in Chap. 7 as a potential target in combination with fractionated radiotherap y for head and neck squamous cell carcinoma (HNSCC). A flurry of agents are under de velopment for targeting EGFR and in March 2006, the US Food and Drugs Administration approved cetuximab combined with radiation as a primary treatment option for patients with loco-regionally advanced HNSCC in whom chemoradiation therapy is deemed not to be an option. While blocking the EGF pathway during fractionated radiotherapy may seem an obvious strategy [5], the rationale for combining antiangiogenic and antivascular targeting agents with radiation may be less intuitive. However, recent research shows that there are several reasons why this could result in a therapeutic gain in practice. Chapter 8 is a review of this rapidly expanding field by Citrin and Camphausen. Targeted agents combined with radiation may offer new opportunities in the treatment of central nervous system malignancies, a tumor type where the outlook remains poor despite some recent progress [6]. Current attempts to overcome rad- tion resistance in these tumors on the basis of an improved understanding of their molecular biology are the topic of Chap. 9 by Chakravarti and Palanichamy.
Additional text
From the reviews:
"Major advances in radiation oncology ... are reviewed in this book. ... Resident, attending and practicing radiation oncologists are the intended audience. The authors are respected radiation oncology practitioners and researchers. ... This excellent account of the major recent advances in radiation oncology is well written and edited. ... It is useful for both practicing and in-training radiation oncologists." (Jyoti Mayadev, Doody's Review Service, December, 2008)
Report
From the reviews:
"Major advances in radiation oncology ... are reviewed in this book. ... Resident, attending and practicing radiation oncologists are the intended audience. The authors are respected radiation oncology practitioners and researchers. ... This excellent account of the major recent advances in radiation oncology is well written and edited. ... It is useful for both practicing and in-training radiation oncologists." (Jyoti Mayadev, Doody's Review Service, December, 2008)
